Orchid Pharma (BOM:524372) Moat Score: 0/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524372 Orchid Pharma Ltd BOM:524372
55 GF Score
Price ₹1,099.65
GF Value ₹835.79
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma Moat Score?

Orchid Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Orchid Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Orchid Pharma might have No Moat - No discernible moat.

Orchid Pharma  (BOM:524372) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Orchid Pharma Moat Score Related Terms

BOM:524372
55GF Score
Orchid Pharma Ltd BOM:524372
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orchid Pharma (BOM:524372) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of ₹1,099.65 is trading 31.6% above its estimated GF Value™ of ₹835.79. GuruFocus considers Orchid Pharma to be Significantly Overvalued.

Key valuation signals for BOM:524372:

  • Moat Score: 0
  • GF Value™: ₹835.79 vs. price of ₹1,099.65 (31.6% above fair value)
  • GF Score™: 55/100 with 10 warning signs

No single metric tells the full story. See the BOM:524372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchid Pharma Business Description

Other Exchanges ORCHPHARMA:India
Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
55GF Score

Get the complete analysis for BOM:524372

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,099.65
Price
₹835.79
GF Value